Evidence map›Paper›PMID 31376158›Full record

ArticleJournal of neurochemistry2020

NYX-2925 induces metabotropic N-methyl-d-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor.

M Scott Bowers, Luisa P Cacheaux, Srishti U Sahu, Mary E Schmidt, Joseph A Sennello, Katherine Leaderbrand, M Amin Khan, Roger A Kroes, Joseph R Moskal

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Effects ofPain reports · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

M Scott BowersFalk Center for Molecular Therapeutics, Biomedical Engineering, Northwestern University, Evanston, Illinois, USA.ORCID 0000-0003-0047-6765
Luisa P CacheauxAptinyx, Inc., Evanston, Illinois, USA.
Srishti U SahuFalk Center for Molecular Therapeutics, Biomedical Engineering, Northwestern University, Evanston, Illinois, USA.
Mary E SchmidtAptinyx, Inc., Evanston, Illinois, USA.
Joseph A SennelloAptinyx, Inc., Evanston, Illinois, USA.
Katherine LeaderbrandAptinyx, Inc., Evanston, Illinois, USA.
M Amin KhanAptinyx, Inc., Evanston, Illinois, USA.
Roger A KroesFalk Center for Molecular Therapeutics, Biomedical Engineering, Northwestern University, Evanston, Illinois, USA.
Joseph R MoskalFalk Center for Molecular Therapeutics, Biomedical Engineering, Northwestern University, Evanston, Illinois, USA.ORCID 0000-0002-4813-3297
Aptinyx (United States) · USNorthwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Andor Revolution XD Live Cell Imaging System with Photomanipulation LaserS10RR031680 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GELFAND, VLADIMIR I · 2011 to 2011
$437k
G-Protein Regulation of Ethanol ActionF32AA015464 · NIAAA · ERNEST GALLO CLINIC AND RESEARCH CENTER · PI BOWERS, MICHAEL SCOTT · 2005 to 2007
$142k
NCI NIH HHS P30 CA060553NCRR NIH HHS S10 RR031680NIAAA NIH HHS F32 AA015464NIAAA NIH HHS L30 AA015858
6 · The paper itself

Abstract

N-methyl-d-aspartate receptors (NMDARs) mediate both physiological and pathophysiological processes, although selective ligands lack broad clinical utility. NMDARs are composed of multiple subunits, but N-methyl-d-aspartate receptor subunit 2 (GluN2) is predominately responsible for functional heterogeneity. Specifically, the GluN2A- and GluN2B-containing subtypes are enriched in adult hippocampus and cortex and impact neuronal communication via dynamic trafficking into and out of the synapse. We sought to understand if ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3,4]octan-2-yl) butanamide (NYX-2925), a novel NMDAR modulator, alters synaptic levels of GluN2A- or GluN2B-containing NMDARs. Low-picomolar NYX-2925 increased GluN2B colocalization with the excitatory post-synaptic marker post-synaptic density protein 95 (PSD-95) in rat primary hippocampal neurons within 30 min. Twenty-four hours following oral administration, 1 mg/kg NYX-2925 increased GluN2B in PSD-95-associated complexes ex vivo, and low-picomolar NYX-2925 regulated numerous trafficking pathways in vitro. Because the NYX-2925 concentration that increases synaptic GluN2B was markedly below that which enhances long-term potentiation (mid-nanomolar), we sought to elucidate the basis of this effect. Although NMDAR-dependent, NYX-2925-mediated colocalization of GluN2B with PSD-95 occurred independent of ion flux, as colocalization increased in the presence of either the NMDAR channel blocker (5R,10S)-(-)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate or glycine site antagonist 7-chlorokynurenic acid. Moreover, while mid-nanomolar NYX-2925 concentrations, which do not increase synaptic GluN2B, enhanced calcium transients, functional plasticity was only enhanced by picomolar NYX-2925. Thus, NYX-2925 concentrations that increase synaptic GluN2B facilitated the chemical long-term potentiation induced insertion of synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor GluA1 subunit levels. Basal (unstimulated by chemical long-term potentiation) levels of synaptic GluA1 were only increased by mid-nanomolar NYX-2925. These data suggest that NYX-2925 facilitates homeostatic plasticity by initially increasing synaptic GluN2B via metabotropic-like NMDAR signaling. Cover Image for this issue: doi: 10.1111/jnc.14735.

Indexed as

AnimalsHippocampusLong-Term PotentiationMaleRatsRats, Sprague-DawleyReceptors, AMPAReceptors, N-Methyl-D-AspartateSignal TransductionSpiro CompoundsSynapsesNR2B NMDA receptorNYX-2925Receptors, AMPAReceptors, N-Methyl-D-AspartateSpiro CompoundsAMPAcolocalizationLTPmetabotropicNMDAtrafficking

Identifiers

PMID31376158
PMCPMC7065110
OpenAlexW2965604479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.